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Background: Irritable bowel syndrome (IBS), a functional gastrointestinal disorder long 
considered a diagnosis of exclusion, has chronic symptoms that vary over time and overlap 
with those of non-IBS disorders. Traditional symptom-based criteria effectively identify IBS 
patients but are not easily applied in clinical practice, leaving .40% of patients to experience 
symptoms up to 5 years before diagnosis.
Objective: To review the diagnostic evaluation of patients with suspected IBS, strengths and 
weaknesses of current methodologies, and newer diagnostic tools that can augment current 
symptom-based criteria.
Methods: The peer-reviewed literature (PubMed) was searched for primary reports and reviews 
using the limiters of date (1999–2009) and English language and the search terms irritable 
bowel syndrome, diagnosis, gastrointestinal disease, symptom-based criteria, outcome, serol-
ogy, and fecal markers. Abstracts from Digestive Disease Week 2008–2009 and reference lists 
of identified articles were reviewed.
Results: A disconnect is apparent between practice guidelines and clinical practice. The Ameri-
can Gastroenterological Association and American College of Gastroenterology recommend 
diagnosing IBS in patients without alarm features of organic disease using symptom-based 
criteria (eg, Rome). However, physicians report confidence in a symptom-based diagnosis 
without further testing only up to 42% of the time; many order laboratory tests and perform 
sigmoidoscopies or colonoscopies despite good evidence showing no utility for this work-up in 
uncomplicated cases. In the absence of diagnostic criteria easily usable in a busy practice, newer 
diagnostic methods, such as stool-form examination, fecal inflammatory markers, and serum 
biomarkers, have been proposed as adjunctive tools to aid in an IBS diagnosis by increasing 
physicians’ confidence and changing the diagnostic paradigm to one of inclusion rather than 
exclusion.
Conclusion: New adjunctive testing for IBS can augment traditional symptom-based criteria, 
improving the speed and safety with which a patient is diagnosed and avoiding unnecessary, 
sometimes invasive, testing that adds little to the diagnostic process in suspected IBS.
Keywords: diagnosis, fecal markers, serum biomarkers, stool forms, symptom-based criteria
Introduction
Irritable bowel syndrome (IBS) is a functional gastrointestinal (GI) disorder character-
ized by abdominal pain or discomfort and altered bowel habits.1,2 As such, IBS occurs 
in the absence of identifiable physical, radiologic, or laboratory indications of organic 
disease.2,3 Characterized as a “brain–gut disorder,”4 IBS is associated with such altered 
physiologic processes as changes in gut motility,5,6 visceral hypersensitivity,7 and Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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altered immune activation of the gut mucosa and intestinal 
microflora.6,8
A recent systematic review of IBS epidemiologic stud-
ies noted an IBS prevalence of 3%–20% in North America, 
with as many as 45 million adults experiencing symptoms 
annually.9 In North America, IBS is more common among 
women than men,2,9,10 is diagnosed more often before age 
50,2,9,10 and appears to be more common in lower socioeco-
nomic populations.11,12
IBS accounts for significant health care resource utili-
zation and economic burden. Although most symptomatic 
individuals do not seek medical care,13 an estimated 3.6 mil-
lion annual physician visits in the United States and US 
$20 billion in annual direct and indirect costs are attributed 
to IBS symptomatology.14 Direct costs are often high in the 
initial diagnostic phase as historically IBS has been consid-
ered a diagnosis of exclusion, prompting sequential testing 
and invasive procedures in an attempt to identify organic GI 
disease.2,3,15 Dean et al16 found that IBS-related symptoms 
reduced work productivity by an estimated 21% per week 
(presenteeism), thus increasing costs to employers. Because 
IBS is not a mortal illness, the impact on patients is often 
underestimated. In reality, however, IBS patients have sub-
stantially poorer health-related quality of life (HRQoL) than 
the general population and HRQoL that is on par with that 
seen in diabetes, depression, and gastroesophageal reflux 
disease.17,18 Furthermore, IBS patients have been noted to 
have worse body pain, lower energy or increased fatigue, and 
poorer social functioning than patients with dialysis-depen-
dent end-stage renal disease.18 Earlier definitive diagnosis 
and institution of appropriate treatment have the capacity to 
reduce some of these consequences of IBS symptoms.16
This article reviews the practical diagnostic evaluation 
of patients presenting with symptoms that may be related 
to IBS, the strengths and weaknesses of current diagnostic 
methodologies, and the newer diagnostic tools that can aug-
ment current symptom-based criteria.
Diagnosis of IBS in clinical practice
Clinical presentation
The hallmark clinical feature of IBS is abdominal pain 
associated with changes in bowel habits.1 Patients with 
symptoms consistent with constipation-predominant IBS 
may describe bloating, feelings that their bowel is being 
incompletely evacuated, and straining, whereas those with 
the diarrhea-predominant form typically report abdominal 
pain, gas, urgency, and loose stools, with more than 30% 
experiencing loss of bowel control.10,19,20 The typical patient 
is a young woman with abdominal discomfort that is relieved 
by passage of multiple loose liquid stools. Her symptoms 
will have been present for more than 3 months and may be 
exacerbated by factors such as fatty foods or stress. Typically, 
no alarm features of organic disease, such as unintentional 
weight loss or rectal bleeding, are present. The clinical course 
of IBS is chronic although symptoms are extremely variable 
and fluctuate over time.21 Nearly half of IBS patients report 
experiencing daily episodes, whereas about 75% experience 
at least two episodes per week.19
Challenges in iBS diagnosis
The symptoms of IBS are heterogeneous, wax and wane 
over time,1,13,22 and frequently overlap and/or coexist with 
symptoms of other common GI and non-GI disorders.22 
Unfortunately, no one symptom or test is pathognomonic for 
IBS. Symptoms of IBS may overlap with symptoms found in 
other disorders, such as chronic constipation, functional dys-
pepsia, gastroesophageal reflux disease, inflammatory bowel 
disease (IBD), celiac disease, and lactose intolerance.22,23 IBS 
can coexist with other functional disorders, most notably 
fibromyalgia, chronic fatigue syndrome, temporomandibular 
joint disorder, and chronic pelvic pain,24,25 and psychologi-
cal conditions, such as anxiety, symptom-related fears, and 
somatization.4,13,24
The differential diagnosis of IBS can be broad3 and may 
include IBD, colorectal cancer, enteric infections, systemic 
hormonal disturbances, and diseases associated with malab-
sorption.2 Alarm features that have traditionally increased 
suspicion for organic disease include rectal bleeding, weight 
loss, iron deficiency anemia, nocturnal symptoms, and a fam-
ily history of such organic diseases as colorectal cancer, IBD, 
and celiac disease.2,13 However, with the exception of anemia 
and weight loss, which have good specificity for organic 
disease, most alarm features have poor overall accuracy for 
organic pathology, including colorectal cancer.2,26
Medicolegal concerns about missing organic pathology 
have contributed to the practice of treating IBS as a diagnosis 
of exclusion,2,3,27 a common approach by many practitioners28 
that leads to unnecessary testing in patients with symptoms 
consistent with IBS and no alarm features. Spiegel28 demon-
strated that physicians who view IBS as a diagnosis of exclu-
sion order 1.6 more diagnostic tests and spend US $364 more 
per patient than those who do not. However, evidence indicates 
that sequential testing is unlikely to uncover the underlying GI 
organic disease in patients without “alarm features,”2,29,30 and 
both the American Gastroenterological Association (AGA) and 
American College of Gastroenterology (ACG) recommend Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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using accepted symptom-based diagnostic criteria to make a 
positive diagnosis of IBS rather than an exhaustive diagnostic 
investigation.2,13,31
Despite testing, or even because of it, the diagnosis of 
IBS is often missed or delayed. In a survey,27 fewer than 
half of 35 health maintenance organization-based family 
practitioners could identify typical IBS symptoms27 and only 
35% knew that the Manning, Rome I, and Rome II criteria 
are used to diagnose IBS. Other physicians report feeling 
comfortable diagnosing IBS at the patient’s first visit only 
40% of the time.32 As a consequence of this lack of diagnos-
tic confidence, more than 40% of patients experience IBS 
symptoms for at least 5 years before diagnosis is made.10,19 In 
addition, these patients endure unnecessary tests, procedures, 
or therapies and the associated financial burden that accom-
panies them.33 Delayed diagnosis can also increase anxiety in 
patients,34 more than half of whom think IBS is a “catch-all” 
diagnosis35 and expect numerous tests to be performed to 
find the “real” diagnosis.34 Common misconceptions about 
the diagnosis and the natural history of IBS negatively affect 
patients’ emotional well-being and HRQoL.35,36
Lacy et al32 analyzed survey responses from 472 gastro-
enterologists, internists, and family physicians to ascertain 
their understanding of IBS and practice patterns. Although 
the physicians reported feeling capable of diagnosing IBS 
at the initial visit without further testing in patients without 
alarm features up to 42% of the time, the majority of gas-
troenterologists report commonly ordering laboratory tests 
and nearly one-third will perform flexible sigmoidoscopies 
or colonoscopies (Figure 1).32 All three types of physicians 
reported a primary goal of excluding organic disease, with 
symptom relief being only of secondary importance. Overall, 
IBS symptoms account for nearly 25% of colonoscopies in 
patients younger than 50 years.2,37,38
Current state of IBS diagnostics
Symptom-based criteria
Several sets of criteria have been developed to identify 
and standardize the diagnosis of IBS (Table 1).2,3 The early 
Manning criteria39 identified six symptoms that increase 
the likelihood of an IBS diagnosis but do not stipulate a 
required number or duration of symptoms. In 1984, Kruis 
et al40 developed a system of symptoms, physical findings, 
and laboratory results, and in 1990, an international working 
group41 developed Rome I criteria in an attempt to reduce 
unnecessary testing and provide a uniform framework for 
selecting patients for diagnostic and therapeutic trials in 
IBS.3,31 These criteria were revised in 1999 by the Rome II 
working group and again in 2006 by the Rome III working 
group (Table 1).1,42 Unfortunately, such criteria can be dif-
ficult to apply in busy practices, and despite extensive use 
in research settings, the Rome II and III criteria are not suf-
ficiently validated.2,3,31 Indeed, only one study evaluated the 
accuracy of the Rome I criteria for diagnosing IBS.43
The utility of symptom-based criteria in primary care 
settings has been brought into question.31,44 As such, alterna-
tive IBS diagnostic criteria have been sought. In one such 
instance, 10 European family practitioners developed a struc-
tured consensus process to define IBS diagnostic criteria. In 
their process, the key features identified for IBS diagnostic 
purposes differed substantially from those stipulated by 
Rome III.44
Traditional diagnostic tests for iBS
The traditional diagnostic work-up of IBS includes common 
tests that may be helpful in differentiating IBS with alarm 
features of organic disease although they are not recom-
mended in patients with typical IBS symptoms who do not 
have alarm features.2,13,43 The choice of test is usually guided 
by the nature and severity of symptoms and the patient’s 
expectations and concerns.2 Advantages and disadvantages 
of these traditional tests are summarized in Table 2.
Newer diagnostic tools, such as the examination of stool 
forms, fecal inflammatory markers, and the use of serum 
biomarker, may be useful adjuncts to traditional evaluations 
of patients with suspected IBS. These simple tests may allow 
clinicians to distinguish IBS from non-IBS disorders in a 
cost-effective manner,45,46 possibly facilitating a paradigm 
shift from approaching IBS as a diagnosis of exclusion to one 
of inclusion.45 Pimentel et al45 have advocated use of specific 
clinical questions regarding bowel form and function that 
may help distinguish between IBS and non-IBS diarrheal 
disease with a high sensitivity. Already used routinely in 
some European countries,47 fecal calprotectin and lactoferrin 
are highly sensitive and specific for intestinal inflammation 
and can differentiate IBD from IBS.23,48 Recently, an IBS 
diagnostic panel composed of 10 serum biomarkers that are 
linked to multiple regulatory pathways and proteins associ-
ated with IBS has been developed. Using a smart diagnostic 
algorithm to interpret the data obtained, this panel may be 
especially helpful in the early stages of the diagnostic process 
in confirming suspected IBS.33
Routine blood and stool hemoccult tests
The AGA recommends a screening of complete blood count 
and stool hemoccult for patients presenting with IBS symptoms Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Figure 1 Laboratory and diagnostic tests commonly ordered, presented by physician type.32 More than 1 response could be chosen. A, Laboratory tests by practice type. 
“Other” laboratory tests (#2%) are not represented. B, Diagnostic tests by practice type. “Other” diagnostic tests (4%–11%) and “no studies ordered” (34%–38%) are not 
represented. P values are shown. 
Abbreviations: Gi, gastrointestinal; CBC, complete blood count; ESR, erythrocyte sedimentation rate; LFT, liver function test; TFT, thyroid function test; FOBT, fecal 
occult blood test; EGD, esophagogastroduodenoscopy; SBFT, small bowel follow-through.
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of short duration, family history of colorectal cancer or IBD, 
older age at symptom onset, or lack of concurrent psychosocial 
difficulties.13 However, these tests offer little value in identifying 
organic disease in patients with typical IBS symptoms but no 
alarm features. In a study of 196 patients with suspected IBS, 
serum chemistries and complete blood counts failed to uncover 
the underlying organic disease in any patient.49 Similarly, a 
review of data from five studies in 2,160 IBS patients showed 
comparable prevalence rates of abnormal thyroid function 
test results between the study patients (4.2%) and the general 
population (5%–9%).2 Further, a causal relationship between the 
thyroid dysfunction and IBS symptoms was not established.2
Stool examinations for ova and parasites
Stool examinations may be useful if the patients’ symptom 
pattern, geographic area, and clinical features (eg, diarrhea 
in an area of known endemic infection) suggest an infectious 
etiology.13 However, such tests are not recommended for routine 
use in patients without alarm features or infection,2,13 as findings 
are significant in fewer than 2% of patients with IBS.2,49,50
Table 1 Comparison of symptom-based criteria
Criteria/y Symptoms, signs, and laboratory  
investigations included in criteria
Symptom duration  
required
Diagnostic performance
Manning et al39 1978 Abdominal pain relieved by defecation; more  
frequent stools with onset of pain; looser stools  
with onset of pain; passage of mucus per rectum;  
feeling of incomplete emptying; patient-reported  
visible abdominal distension
None Sensitivity 78%,  
specificity 72%, positive  
LR 2.9 (95% Ci, 1.3–6.4)31
Kruis et al40 1984 Symptoms (reported by patient using a form):  
abdominal pain, flatulence, or bowel irregularity;  
description of abdominal pain as burning, cutting,  
very strong, terrible, feeling of pressure, dull,  
boring, or “not so bad”
Signs (determined by physician): abnormal physical  
findings and/or history; pathognomonic for any  
diagnosis other than iBS; ESR .20 mm/2 h;  
leukocytosis .10,000 cells/µL; anemia (hemoglobin  
,12 g/dL for women, ,14 g/dL for men); physician  
impression is that patient’s history suggests  
blood in the stools
.2 yr Sensitivity 77%,  
specificity 89%, positive  
LR 8.6 (95% Ci, 2.9–26.0)31
Rome i criteria41 1990 Abdominal pain or discomfort relieved with  
defecation or associated with a change  
in stool frequency or consistency; any variation  
in defecation on $25% of occasions evidenced  
by 3 of the following:  
  Altered stool frequency 
  Altered stool form 
  Altered stool passage 
  Passage of mucus per rectum 
  Bloating or distension
$3 mo Sensitivity 65%, specificity  
100%, PPv 100%43
Rome ii criteria13,42 1999 Abdominal discomfort or pain that has  
2 of 3 features:  
  Relieved with defecation 
  Onset associated with a change in stool frequency 
  Onset associated with a change in stool form
$12 wk (need not  
be consecutive  
in past year)
Not validated
Rome iii criteria1 2006 Recurrent abdominal pain or discomfort  
$3 d/mo in the past 3 mo associated  
with $2 of the following: 
  improvement with defecation 
  Onset associated with a change in stool frequency 
  Onset associated with a change in stool form
Symptom onset:  
$6 mo before  
diagnosis
Not validated
Adapted with permission from Ford AC, Talley NJ, veldhuyzen van Zanten SJ, vakil NB, Simel DL, Moayyedi P. will the history and physical examination help establish that 
irritable bowel syndrome is causing this patient’s lower gastrointestinal tract symptoms? JAMA. 2008;300(15):1793–1805.31 Copyright © 2008 American Medical Association. 
All rights reserved.
Abbreviations: Cl, confidence interval; LR, logistic regression; IBS, irritable bowel syndrome; ESR, erythrocyte sedimentation rate; PPv, positive predictive value.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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Carbohydrate breath test
The carbohydrate breath test has been used by gastroenter-
ologists for many years to detect lactose malabsorption. The 
test measures exhaled levels of hydrogen and/or methane 
produced during the metabolism of carbohydrate substrates 
by intestinal bacteria.51 Breath testing for lactose intolerance 
may be useful in patients with typical IBS symptoms and 
suspected lactose maldigestion. It is important, however, to 
establish that dietary intake of lactose is .240 mL of milk 
(or equivalent) per day before testing for lactose intolerance, 
as Suarez et al52 have shown that patients with documented 
lactose malabsorption are able to tolerate 240 mL of milk 
per day with minimal or no symptoms. A systematic review 
of data from seven studies involving 2,149 IBS patients 
demonstrated a 35% prevalence of lactose maldigestion (95% 
confidence interval [CI]: 17–56) by lactose breath testing,2 
whereas a separate analysis of three case-control studies 
involving 425 patients (251 of whom had IBS) revealed 
a prevalence of 38% in IBS patients vs 26% in controls 
(odds ratio [OR] = 2.57; 95% CI: 1.27–5.22).2 Despite the 
frequent occurrence of lactose intolerance in patients with 
IBS, no causal relationship has been established between 
lactose intolerance and IBS symptoms. However, given the 
possibility that IBS patients are more sensitive to the clinical 
consequences of lactose maldigestion,53 the ACG IBS Task 
Force has recommended considering a lactose hydrogen 
breath test in patients whose history and food diary review 
suggest potential lactose maldigestion.2
Recently, carbohydrate breath test has been used in an 
attempt to identify patients with small intestinal bacterial 
overgrowth (SIBO).51 Emerging evidence suggests that SIBO 
plays a pathogenic role in IBS,54,55 although this remains 
contentious. The use of carbohydrate breath test to diagnose 
SIBO in IBS patients has yielded conflicting results. In a sys-
tematic review by the ACG IBS Task Force, the prevalence of 
a positive lactulose breath test was 65% (95% CI: 47–81) in 
432 IBS patients from three studies, whereas the prevalence 
of a positive glucose breath test was 36% (95% CI: 29–43) 
in 208 patients from two studies.2 Because lactulose is not 
absorbed by the intestine, lactulose breath tests should detect 
bacteria anywhere along the gut.51,56 Because glucose is 
absorbed rapidly, glucose breath testing can detect bacteria 
only in the duodenum and proximal jejunum, demonstrating 
lower sensitivity than lactulose breath testing.51,56 Posserud 
et al57 used jejunal aspirate culture to assess the prevalence 
of SIBO in 162 patients with IBS and found a prevalence of 
Table 2 Comparison of traditional diagnostic methods
Tests Advantages Disadvantages
CBC, TSH, serum  
chemistries, FOBT
inexpensive Limited value in identifying organic disease   
in patients without alarm features2
Stool for ova and parasites Noninvasive, inexpensive
May be useful in patients with  
clinical features, symptom pattern, and  
geographic area suggestive of infection13
Limited value in identifying organic disease   
in patients without alarm features2
Hydrogen breath tests May be useful when lactose maldigestion  
is suspected51,56 
Noninvasive
Need for specialized equipment, dedicated   
space, and technical support51 
False-positive results possible in smokers  
and those with poor oral hygiene51 
Limited value in identifying organic  
disease in patients without alarm features2
Celiac serologies  
(anti-tTG, EMA, AGA)
Routine use in iBS-D and iBS-M patients  
helpful in identifying celiac disease2,58
–
Abdominal imaging May be useful in excluding mechanical obstruction  
in patients with iBS-C and alarm features2
Expensive 
Low diagnostic yield in patients  
without alarm features29
Endoscopy/colonoscopy Useful for identifying organic diseases (particularly  
iBD, colorectal cancer, and microscopic colitis) in  
patients with iBS-D and alarm features2 
Can exclude mechanical obstruction in patients with  
iBS-C and alarm features2  
Upper endoscopy with biopsies may be useful  
in detecting celiac disease or SiBO2
Expensive
Low diagnostic yield in patients  
without alarm features3,49 
Normal findings not associated with  
improved HRQoL37
Abbreviations: CBC, complete blood count; TSH, thyroid-stimulating hormone; FOBT, fecal occult blood test; anti-tTG, antibodies to tissue transglutaminase; EMA, 
endomysial antibodies; AGA, antigliadin antibodies; iBS, irritable bowel syndrome; iBS-D, diarrhea-predominant iBS; iBS-M, mixed iBS; iBS-C, constipation-predominant iBS; 
IBD, inflammatory bowel disease; SIBO, small intestinal bacterial overgrowth; HRQoL, health-related quality of life.Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
133
irritable bowel syndrome: diagnostic approaches
SIBO (defined as $105 colony-forming units [CFU]/mL) 
of 4% in patients with IBS (7 of 162) and in controls (1 of 
26). Glucose hydrogen breath testing performed on 54 IBS 
patients and 20 controls with ,105 CFU/mL was positive in 
only one IBS patient; lactulose hydrogen breath testing in 
46 IBS patients and 21 controls with ,105 CFU/mL yielded 
positive results in 15% (7 of 46) of IBS patients and 20% 
(4 of 21) of controls.57 The ACG IBS Task Force does not 
recommend breath testing for SIBO in patients with IBS.2
Celiac testing
The prevalence of serologic evidence of celiac disease among 
IBS patients (endomysial antibodies [EMA] or tissue trans-
glutaminase antibodies [anti-tTG]) is more than three fold 
higher than among controls without IBS, and the prevalence 
of biopsy-proven celiac disease is four fold higher than among 
controls.58 Routine serologic screening for celiac disease is 
recommended for patients with diarrhea-predominant IBS 
(IBS-D) or mixed features of IBS (IBS-M).2 EMA and anti-tTG 
have a higher positive predictive value for celiac disease than 
the immunoglobulin (Ig) A-class antigliadin antibodies.58
imaging
Neither abdominal nor colonic imaging tests are likely to 
reveal the structural abnormalities that explain symptoms 
of IBS in patients with no alarm features.2,29 In a study of 
125 patients with suspected IBS on the basis of the Rome 
I criteria, abdominal ultrasound failed to reveal any serious 
intra-abdominal pathology.29 Although abnormalities were 
detected in 18% of patients, findings did not change a diag-
nosis.29 In three studies, in a total of 636 IBS patients, imag-
ing with barium enema or colonoscopy revealed organic or 
structural disease in 1.3% of patients, which does not exceed 
the prevalence in the general population.2
Endoscopy or colonoscopy
Studies evaluating endoscopic investigation for suspected 
IBS do not support their routine use in patients without alarm 
features. Hamm et al50 assessed the value of such tests as flex-
ible sigmoidoscopies, barium enemas, and colonoscopies in 
1,452 patients meeting Rome criteria for at least 6 months. 
Among the 306 patients undergoing colonic examination, 
abnormalities were detected in seven patients (2%): IBD in 
three, colonic obstruction in one, and colonic polyps with-
out malignancy in three.50 In a smaller study of 196 patients 
with IBS, 43 colonic structural abnormalities were found 
in 34 patients. Nine (26%) of these patients had indicators 
suggestive of organic disease49 and, of these, only two (1%) 
had abnormalities (one   colitis, one colon cancer) that may 
have caused IBS symptoms.3,49 MacIntosh et al59 performed 
flexible sigmoidoscopy with rectal biopsy in 89 patients with 
IBS, most of whom met Rome I criteria. None of the findings 
suggested alternative diagnoses that could account for the GI 
symptoms in any patient. Investigators concluded that such 
studies are costly and unnecessary in IBS.3,59 A retrospective 
review37 of data from 458 patients found that colonoscopy had 
a low diagnostic yield and normal findings were not associated 
with higher HRQoL owing to diagnostic reassurance.
Based on these and other findings, patients younger than 
50 years with IBS symptoms but no alarm features do not 
require routine colonic imaging. However, patients aged > 50 
years (45 years in African Americans) should follow expert 
recommendations for colonic imaging for colorectal cancer 
screening2,38,60 and those aged > 50 years with alarm features 
should undergo colonoscopy to rule out organic disease.2
Patients with IBS-D and alarm features should be exam-
ined specifically for colorectal cancer and IBD and potentially 
undergo random mucosal biopsies to rule out microscopic 
colitis, which has a prevalence of 2.3% among patients with 
IBS-D.2,61 The prevalence of microscopic colitis is highly 
age-dependent as shown in a Swedish epidemiology study 
of 1,018 patients presenting with nonbloody diarrhea who 
underwent colonoscopy; 10% overall, but 20% of those .70 
years, received a diagnosis of microscopic colitis.62 Patients 
with IBS-C should be evaluated for mechanical obstruction, 
which can be done by colonoscopy, virtual colonography, or 
barium enema.2 Upper endoscopy with small bowel biop-
sies can be considered to test for celiac disease or SIBO 
in patients with laboratory or stool findings suggestive of 
malabsorption.2
Newer, innovative tests for iBS
Several noninvasive diagnostic approaches were investigated 
for their ability to discriminate IBS from non-IBS disorders. 
Although more data are needed,45,48 these tests show potential 
as adjuncts to traditional diagnostic methods in IBS33,63 and 
may reduce unnecessary testing in clinical practice.33,45,46
Examination of stool forms
Pimentel et al45 evaluated the variations in frequency and 
consistency of bowel habits over time to distinguish diarrhea 
secondary to IBS from diarrhea associated with active celiac 
disease, ulcerative colitis (UC), and Crohn’s disease. The 
basis for this testing is that patients with IBS-D, whose bowel 
function varies with changes in neuromuscular   function, will 
more likely experience irregular bowel function and stool Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
Dovepress 
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form than those with non-IBS causes of diarrhea. Sixty-two 
IBS-D patients and 37 non-IBS patients (UC, Crohn’s 
disease, celiac disease) completed a questionnaire on their 
bowel habits and stool forms during the preceding week. 
More IBS than non-IBS patients reported daily variations 
in stool form and frequency of bowel habits (79% vs 35%; 
P , 0.00001).45 Further, 81% of IBS patients and 41% of 
those without IBS reported having at least three stool forms 
per week; the difference of three stool forms per week has 
a sensitivity of 68% and specificity of 84% in differentiat-
ing IBS.45 The success of this simple tool in distinguishing 
between IBS and non-IBS diarrheal disease may help avoid 
unnecessary diagnostic testing.45
Fecal markers
Increasing evidence supports the utility of fecal calprotec-
tin and lactoferrin in differentiating between IBD and IBS 
because these markers can identify active intestinal inflam-
mation in IBD.23,48,63–65 Easily measured in feces, calprotectin 
and lactoferrin are stable, neutrophil-derived proteins that 
increase in concentration in response to leukocyte migration 
into the gut.48,64,66
Tibble et al46 examined the diagnostic efficacy of fecal 
calprotectin in 602 patients referred to a gastroenterology 
clinic. With a cutoff value of 10 mg/L, calprotectin had an 
89% sensitivity and a 79% specificity for organic disease (ie, 
IBD) with an OR of 27.8 (95% CI: 17.6–43.7; P , 0.0001). 
Other investigators demonstrated similar diagnostic utility of 
these fecal markers to differentiate active IBD from inactive 
disease and from IBS.64,65 Schoepfer et al23 prospectively 
found fecal calprotectin and lactoferrin levels in patients with 
IBD to be over the levels in patients with IBS and in healthy 
controls, but did not differ between IBS patients and healthy 
controls. Although the elevated levels of fecal calprotectin 
and lactoferrin are potentially valuable when screening for 
intestinal inflammation and discriminating between organic 
and functional diseases,46,48 neither the cause of the inflam-
matory process leading to the elevations can be discerned 
with these markers nor are the elevations able to “rule in” 
a diagnosis of IBS, given that differences between IBS and 
healthy controls are not significant.
Serologic markers
A number of altered physiological pathways have been 
identified in patients with IBS. The major pathogenic pro-
cesses include altered gut motility and visceral hypersen-
sitivity, which are believed to be due to the dysregulation 
of   brain–gut axis pathways,67 immune dysregulation in the 
GI tract,68 altered gut flora,2,54,56,69 and complex interactions 
between neuronal and hormonal factors.33 These alterations 
have prompted investigations of IBS biomarkers that may 
help elucidate the pathophysiology of the disorder68 and aid 
in the diagnosis of the disease.33
Lembo et al33 described a panel of 10 serum biomark-
ers that may be useful to help differentiate IBS from 
non-IBS disease and healthy controls. This biomarker 
panel was derived from a literature review, which identi-
fied .60,000 possible biomarkers common to IBS and 
other GI diseases (both functional and organic) and part 
of the differential diagnosis in suspected IBS. Subse-
quently, this group of biomarkers was further refined to 
140 biomarkers by identifying those that were common 
across multiple pathways, those that were serum based, 
and those for which assays were commercially avail-
able. Assays of these 140 biomarkers in IBS and control 
samples resulted in significant median differences in 16 
biomarkers. Expression values of these 16 biomarkers 
were then evaluated in .300,000 algorithms, ultimately 
identifying 10 biomarkers, the combined performance of 
which provided the greatest accuracy in distinguishing 
IBS patients from non-IBS patients. The panel includes 
interleukin-1β, growth-related oncogene-α, brain-derived 
neurotrophic factor, antihuman anti-tTG, tumor necrosis 
factor-like weak inducer of apoptosis, tissue inhibitor 
of metalloproteinase-1, neutrophil gelatinase-associated 
lipocalin, antibody to bacterial flagellin (anti-CBir1), 
anti-Saccharomyces cerevisiae antibody (ASCA-IgA), 
and antineutrophil cytoplasmic antibody (ANCA).33 Six 
of these biomarkers have been associated with metabolic 
dysregulation in IBS, whereas others (ASCA, ANCA, 
and anti-CBir1) have typically been associated with IBD. 
Notably, one study demonstrated elevated levels of anti-
CBir1 in a subset of patients with postinfectious IBS, 
presumably the result of bacterial infection and immune 
system activation.70 The role of inflammatory processes 
in IBS and concomitant changes in biomarker expression 
need to be more fully evaluated, especially as they relate to 
potential changes over the course of the disease. Likewise, 
anti-tTG is a serum antibody known to be highly specific 
for only celiac disease.
After the biomarkers were identified, a predictive model-
ing tool was used to discern patterns of serum concentrations 
that best differentiated IBS patients from those with non-
IBS GI disease (IBD, non-IBS functional GI disorders, and 
celiac disease) and healthy controls in a training cohort of 
1,205 patients.33 This model was then validated in a different Clinical and Experimental Gastroenterology 2010:3 submit your manuscript | www.dovepress.com
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cohort of 516 patients with IBS or a non-IBS GI disease and 
healthy controls. The overall diagnostic accuracy of this test 
in differentiating IBS from non-IBS was 70% (sensitivity 
50%, specificity 88%), and at a 50% IBS prevalence, the 
positive predictive value was 81% and the negative predic-
tive value was 64%, leading investigators to conclude that 
a positive test result can help confirm a suspicion of IBS 
although the sensitivity is insufficient for a negative test to 
reliably exclude the diagnosis.33 Although not appropriate 
for use as a single diagnostic tool, this biomarker panel may 
be a cost-effective adjunct to traditional diagnostic methods 
in an overall work-up of IBS.33 A systematic review and a 
meta-analysis examining various diagnostic criteria in IBS 
have reported that the Manning, Kruis, and Rome I criteria 
have similar positive and negative likelihood ratios of pre-
dicting an IBS diagnosis in comparison to the 10-biomarker 
diagnostic panel.31,71 As the only serologic test that “rules 
in” IBS, the panel may provide optimal utility early in the 
disease course, avoiding more expensive and invasive test-
ing, introducing greater confidence in a “correct” diagnosis, 
and allowing earlier initiation of an appropriate treatment 
plan. As the biomarker test evolves through scientific and 
technologic advances, sensitivity and specificity should 
improve33 and lead to better clinical trials and quality of life 
for patients with IBS.
Conclusion
The substantial human and economic cost associated with 
IBS necessitates development of efficient diagnostic and 
management strategies.37 Although among the most common 
disorders in gastroenterology and primary care practices, 
IBS continues as a substantial diagnostic challenge. A lack 
of confidence in symptom-based diagnosis, a broad differen-
tial diagnosis, patient misconceptions and expectations, and 
medicolegal concerns about missing organic disease may all 
contribute to unnecessary and costly diagnostic testing.2,27,34 
Nevertheless, the diagnosis of IBS is often missed or 
delayed. Innovative diagnostic tests, such as examination of 
stool forms, fecal markers of inflammation, and IBS serol-
ogy, offer promise as noninvasive, cost-efficient adjuncts 
to traditional diagnostic methods, particularly early in the 
disorder.
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